[
  {
    "ts": null,
    "headline": "Incyte: Buy For The Turnaround, Stay For The Pipeline",
    "summary": "Incyte Corporation rated Strong Buy: Jakafi resilience, 45% ex-Jakafi growth, pipeline catalysts and low 13.7x EPS valuation. Click for this INCY stock update.",
    "url": "https://finnhub.io/api/news?id=456188319d021ee8f3018e2f6692fa748f149defd0b462c48dbf614e0d92bf2b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768570495,
      "headline": "Incyte: Buy For The Turnaround, Stay For The Pipeline",
      "id": 138154559,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1493093304/image_1493093304.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyte Corporation rated Strong Buy: Jakafi resilience, 45% ex-Jakafi growth, pipeline catalysts and low 13.7x EPS valuation. Click for this INCY stock update.",
      "url": "https://finnhub.io/api/news?id=456188319d021ee8f3018e2f6692fa748f149defd0b462c48dbf614e0d92bf2b"
    }
  },
  {
    "ts": null,
    "headline": "XPH: Healthcare Dashboard For January",
    "summary": "The State Street SPDR S&P Pharmaceuticals ETF provides equal-weight exposure and cuts single-stock risk. Click here to read my latest analysis of XPH.",
    "url": "https://finnhub.io/api/news?id=88a66b183c88d1dec9678cebfd94abf7fdd27ceb7d9b4ff3369fa886b09cba9c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768566072,
      "headline": "XPH: Healthcare Dashboard For January",
      "id": 138153468,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1434365911/image_1434365911.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "The State Street SPDR S&P Pharmaceuticals ETF provides equal-weight exposure and cuts single-stock risk. Click here to read my latest analysis of XPH.",
      "url": "https://finnhub.io/api/news?id=88a66b183c88d1dec9678cebfd94abf7fdd27ceb7d9b4ff3369fa886b09cba9c"
    }
  },
  {
    "ts": null,
    "headline": "Incyte's Pipeline Potential Signals Massive Upside For Investors",
    "summary": "Incyte (INCY) outlook: profitable biotech with expanding Opzelura/oncology growth, key 2026â2030 catalysts, and 33% upsideâread now.",
    "url": "https://finnhub.io/api/news?id=bfc277e926fb5597603729f2f4de467706e75e48bf683b6c28b02a363f3dcaf0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768551357,
      "headline": "Incyte's Pipeline Potential Signals Massive Upside For Investors",
      "id": 138151446,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150976233/image_2150976233.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyte (INCY) outlook: profitable biotech with expanding Opzelura/oncology growth, key 2026â2030 catalysts, and 33% upsideâread now.",
      "url": "https://finnhub.io/api/news?id=bfc277e926fb5597603729f2f4de467706e75e48bf683b6c28b02a363f3dcaf0"
    }
  }
]